Background: MicroRNAs (miRNAs) play an important role in the regulation of cell proliferation, apoptosis, development and differentiation. Several studies have shown that aberrant expression of miRNAs is involved in cancer development and progression by regulating the expression of proto-oncogenes or tumor suppressor genes. In this study, we investigated miRNA expression profiles in Korean patients with non-small cell lung cancer (NSCLC). Methods: We performed miRNA microarray analysis containing 60∼65 bp oligonucleotide probes representing human 318 miRNAs and validated the results of the microarray with Northern blot analysis or quantitative RT-PCR. Next, we examined the correlation between miRNA expression and the target gene transcriptional profile using a human whole-genome-expression microarray. Results: We showed that 35 miRNAs were expressed differentially in the NSCLCs and corresponding non-malignant lung tissues. We showed that 35 miRNAs were expressed differentially in the NSCLCs and corresponding nonmalignant lung tissues. Thirteen of the 35 differentially expressed miRNAs were newly identified in the present study. Of the 35 miRNAs, 2 (miR-371 and miR-210) were over-expressed in lung cancers, and 33 miRNAs, including miR-145, were under-expressed in lung cancers. miR-99b expression consistently showed a negative correlation with FGFR3 expression.
Introduction
MicroRNAs (miRNAs) are noncoding, single-stranded RNAs of ∼22 nucleotides that repress gene expression by interacting with messenger RNA (mRNA), either by inhibiting mRNA translation or by inducing mRNA cleavage [1] [2] [3] . To date, more than 400 human miRNAs have been identified and up to 30% of all protein-coding genes are estimated to be regulated by miRNAs 2, 4, 5 . Although the precise functions of individual miRNAs have not been characterized, biochemical and genetic studies have revealed that miRNAs regulate a variety of biological processes, such as cell proliferation, apoptosis, development and differentiation [6] [7] [8] [9] . miRNA genes are frequently located at chromosomal regions, such as fragile sites, and regions of deletion or amplification that are genetically altered in human cancer 10, 11 . In addition, it has been reported that some miRNAs are aberrantly expressed or mutated in human cancers, suggesting that they may function as either oncogenes or tumor suppressor genes; depending on the targets they regulate [12] [13] [14] . The first evidence of the involvement of miRNAs in cancer came from a study characterizing the 13q14 deletion in chronic lymphocyte leukemia, which revealed that two clustered miRNA genes, miR-15a and miR-16-1, are the target genes of the 13q14 deletion 15 . Subsequently, deregulation of miRNA has been found in various human cancers including lung cancer, such as the down-regulation of let-7 in lung cancer 16, 17 , up-regulation of the miR-17-92 cluster in B-cell lymphoma and lung cancer 18, 19 , and down-regulation of miR-143 and miR-145 in colorectal cancer 20 . Using miRNA microarray technology, several groups have revealed miRNA expression profiles in many human cancers [21] [22] [23] [24] [25] , and also identified miRNA expression signatures associated with clinical and pathological features as well as disease outcome [21] [22] [23] . Although miRNA expression profiles have been studied in lung cancer, the majority of the previous studies were performed on Western populations 21, 22, 26 . The epidemiological characteristics of lung cancer in East Asian countries are different from those reported from Western countries. For example, lung adenocarcinoma in women, in East Asian countries, frequently develops in never-smokers 27, 28 . In addition, several recent studies have shown that mutations in the kinase domain of the epidermal growth factor receptor gene are more frequent in never-smokers, females and East Asian populations, whereas KRAS mutations are more frequent in smokers, males and Western populations 29, 30 . These observations, coupled with the differences in the epidemiological characteristics of lung cancer, suggest that the genetic and environmental factors leading to lung cancer in East Asian populations may be different from those of Western populations 29, 30 . Therefore, it is possible that miRNA expression profiles in lung cancer among East Asian populations may be different from Western countries. In this study, we investigated the miRNA expression profiles in Korean patients with non-small cell lung cancers (NSCLCs). 
miRNA extraction
The total RNA of each sample was extracted using the Trizol reagent (Life Technologies, Carlsbad, CA, USA) according to the instructions of the manufacturer. Low molecular weight (LMW) enriched RNA was isolated from 50 μg of total RNA using the mirVana miRNA extraction kit (Ambion Inc., Austin, TX, USA), and quantified using a ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNA quality was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
miRNA microarray hybridization
The expression of miRNAs was profiled using a miRNA microarray chip (Genomic Tree Inc., Seoul, Korea) containing 60∼65 bp oligonucleotide probes representing human 318 miRNAs. Briefly, 1 μg of LMW RNA was labeled using a ULS TM small RNA labeling kit The hybridization signals were analyzed using a GenePix Pro 6.0 program (Axon Instruments, Foster City, CA, USA). The average fluorescence intensity for each spot was calculated and then the local background was subtracted. All data mining and selection of fold-changed genes were performed using GeneSpringGX 7.3 (Agilent Technologies). Genes were filtered with cut-off values based on the sum of the median of ≥1,000 in each experiment. The averages of the ratios were calculated by dividing the average of the signal channel intensity by the average of the control channel intensity. We considered the results from the Significance Analysis of Microarray 3.0 (SAM) with genes of ratios (Cy5/Cy3) either ≥2.0 or ≤0.5 from ≥5 of 7 tumor samples as significantly different in expression.
Northern blotting and qRT-PCR
To validate the microarray analysis results, we carried out Northern blot analysis on two (miR-145 and miR-210) of the 35 differentially expressed miRNAs using a mirVana miRNA detection kit (Ambion Inc.). Briefly, 3 μg of total RNA was hybridized with 1 pM RNA probe (miR-145, biotin-5'-AAAAGGGAUUCCUGGGAAAACUG GAC-3'; and miR-210, biotin-5'-AAAAUCAGCCGCUGUC ACACGCACAG-3'). The 5S RNA probe (biotin-5'-AAAA UGAUCUCGGAAGCUAA-3') was used to normalize the level of expression. To remove unhybridized RNA, the RNAase A/T1 solution was added, followed by alcohol precipitation. Hybridized RNA was separated on a 15% denaturing polyacrylamide gel and then electroblotted on a Hybond-Nylon membrane (Amersham Biosciences, Buckinghamshire UK). Detection of hybridized RNA was performed using a non-radioactive LightShift Chemiluminescent kit (Pierce Biotechnol Inc., Rockford, IL, USA). The membrane was UV cross-linked, and the biotin end-labeled hybridized RNA was detected with streptavidin-HRP using a luminal enhancer solution. qRT-PCR analysis for miRNAs was performed in duplicate with a TaqMan MicroRNA assay kit (Applied Biosystems, Foster City, CA, USA) according to the instructions of the manufacturer, and 18S RNA was used for normalization.
Human whole genome expression microarray
For hybridization onto an Agilent Whole Human Genome 4×44 K 60 mer oligonucleotide array (G4112F; Agilent Technologies), 1 μg of total RNA was used in the Agilent LIRAK PLUS with the two-color Low RNA input Linear Amplification method, according to the manufacturer's instructions. Briefly, the total RNA was reverse transcribed into complimentary DNA (cDNA) using a T7-promotor primer and MMLV reverse transcriptase. The cDNA was transcribed into complimentary RNA (cRNA), during which the cDNA was fluorescently labeled by incorporation of cyanine Cy5-CTP (lung cancer tissue) or Cy3-CTP (normal lung tissue). After purification, using the RNeasy mini kit (Qiagen), the cRNA yield and Cy incorporation efficiency (specific activity) into the cRNA were determined using a NanoDrop Spectrophotometer (NanoDrop Technologies). cRNAs showing a yield ＞825 ng and a specific activity of 8∼ 20 pmol/μg cRNA were selected for further processing. Equal amounts of the exposed and negative control sample were competitively hybridized onto Agilent Whole 4×44 K human oligonucleotide arrays in a hybridization oven at 60 o C for 17 h. Slides were washed according to the manufacturer's instructions with washing buffers and finally dipped in Stabilization and Drying Solution (Agilent Technologies) for protection from environmental ozone. The arrays were scanned on an Agilent scanner (G2565BA) and further processed using Agilent Feature Extraction Software (version 9.5.1).
Results
To generate miRNA expression profiles for NSCLC, we analyzed the expression of 315 human miRNAs using oligonucleotide microarray hybridization chips in 7 pairs of primary lung cancers and corresponding non-malignant lung tissues (Figure 1 ). We identified 35 miRNA genes that were differentially expressed in the NSCLCs and corresponding non-malignant lung tissues with ratios (Cy5/Cy3) either ≥2 fold or ≤0.5 fold from at least 5 of 7 tumor samples ( Table 2 ). Among the 35 differentially expressed miRNAs, two (miR-371 and miR-210)
were over-expressed in lung cancers, and 33 miRNAs, including miR-145, were under-expressed in lung cancers. Among the 35 differentially expressed miRNAs, 13 of the miRNAs have not been previously reported to be altered in lung cancer; miR-376b, miR-144, miR-520d-5p, miR-520e, miR-520f, miR-23a, miR-296-5p, miR-133a-2, miR-99b, miR-497, miR-425, and miR-338-3p were downregulated, and miR-371-3p was up-regulated.
To validate the microarray results, the expression of representative miRNAs were determined using Northern blot analysis (miR-210 and miR-145) and qRT-PCR (miR-210 and miR-29c). Consistent with the results of the microarray analysis, miR-210 was up-regulated in the lung cancers, and miR-145 and miR-29c were down-regulated in the lung cancers (Figure 2) .
We predicted tumor-associated target genes of the new 13 miRNAs using 3 public algorithms (MIRAND 31 , TARGETSCAN 32 , and PICTAR 33 ). The list of putative target genes of 5 miRNAs (miR-144, miR-23a, miR-99b, miR-133a-2, and miR-296-5p), which were predicted by at least 2 of the 3 programs, are shown in Table 3 . We next examined the correlation between miRNA expression and target gene transcriptional profiles. Of the 5 miRNAs, miR-99b expression consistently showed a negative correlation with fibroblast growth factor re- ceptor 3 (FGFR3) expression (Table 3) .
Discussion
We performed miRNA expression profiling using microarray analysis in Korean patients with NSCLC and identified a number of miRNAs that were differentially expressed in NSCLCs. To date, two large studies on miRNA expression profiles in lung cancer have been reported 22, 26 . In a study of 104 matched pairs of lung cancers and non-cancerous lung tissues, Yanaihara et al 22 identified a set of 43 differentially expressed miRNAs; 28 were down-regulated and 15 were up-regulated. The majority of the miRNAs detected in the present study were the same miRNAs that were identified by Yanaihara et al 22 . For example, miR-145, miR-181c, miR-30 family, miR-140, miR-143, miR-125, miR-126, miR-101, miR-95, miR-9, and miR-125a were down-regulated and miR-210 was up-regulated in both studies (Table 2 ). In addition, we found that let-7f was down-regulated in lung cancer tissues, which was also consistent with the results of Yanaihara et al 22 , where let-7a-2 was downregulated in lung cancer. Volinia et al 26 also found that lung cancer cells showed distinct miRNA profiles compared to normal cells in a study of 80 lung cancers and 40 normal lung tissues. They reported that 3 miRNAs were down-regulated and 35 miRNAs were over-expressed in lung cancers. When our data were compared with the results of the study reported by Volinia et al 26 , several miRNAs showed the opposite results of up-regulation or down-regulation. For example, they reported that let-7a, let-7g, miR-142 and miR-9-1 were up-regulated in lung cancers. However, these miRNAs were down-regulated in lung cancers in the present study, as well as in the study reported by Yanaihara et al 22 . This discrepancy may be due to differences in the methods used in the studies. Volinia et al 26 measured the expression of both the pri-miRNAs and the active mature miRNAs simultaneously. Considering that the pri-miRNAs are transient products in miRNA biogenesis, and presumably are rapidly further processed after synthesis 34 , the expression status of the pri-miRNA and the mature miRNA is not necessarily the same. Therefore, the profiles of the combined expression of the pri-miRNAs and the mature miRNAs may be different from the expression of the mature miRNAs 24 . Racial differences in miRNA expression were reported in uterine leiomyomas. Wang et al 35 found that substantial number of miRNAs that are significantly differently regulated between black and white women. Black women had a greater than 2-fold overexpression in miR-23a/b, let-7s, miR-145, miR-197, miR-411, and miR-412. In the present study, we found that miR-376b, miR-144, miR-520d-5p, miR-520e, miR-520f, miR-23a, miR-296-5p, miR-133a-2, miR-99b, miR-497, miR-425, and miR-338-3p were down-regulated and miR-371-3p was up-regulated. To characterize these miRNA, we analyzed their chromosomal location. miR-520d-5p, miR520e, miR-520f, miR-99b, miR-371-3p were located in 19q13.43. The results of this study showed that miR-99b was down-regulated in NSCLCs and the expression was negatively correlated with FGFR3 expression. FGFR3 belongs to a family of structurally-related tyrosine kinase receptors (FGFR1∼4) involved in many aspects of embryogenesis and tissue homeostasis. These receptors regulate various biological processes, including proliferation, differentiation, angiogenesis, migration, and apoptosis 36 . FGFR3 has been demonstrated to be involved in the RAS/RAF/MEK/MAPK pathway through activation of p90 ribosomal S6 kinase 37 . In addition, it has been reported that FGFRs are frequently overexpressed in NSCLC cell lines, suggesting that an FGFR-dependent autocrine signaling pathway may operate in a subset of NSCLCs 38 . Based on these observations, it is possible that miR-99b may be involved in lung tumorigenesis through up-regulation of FGFR3.
Albeit a small number of patients were examined, these results suggest that miRNA expression profiles in Korean lung cancers may be somewhat different from the expression profiles reported on lung cancers in Western populations. The findings suggest that miR-99b might be a tumor suppressor through its up-regulation of FGFR3.
